Health Affairs, 24, no. 1 (2005): 67-78 doi: 10.1377/hlthaff.24.1.67 © 2005 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Fleming, T. R. Search for Related Content PubMed PubMed Citation Articles by Fleming, T. R. Related Collections Evidence-Based Medicine Health Reform Physicians Quality Of Care Research And Technology Politics

Case Studies

Surrogate Endpoints And FDA’s Accelerated Approval Process

There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential "surrogates" for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention’s safety and efficacy.

                      What's this?

This article has been cited by other articles:

				M. N Lassere The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints Statistical Methods in Medical Research, June 1, 2008; 17(3): 303 - 340. [Abstract] [PDF]

				T. R Fleming, K. Sharples, J. McCall, A. Moore, A. Rodgers, and R. Stewart Maintaining confidentiality of interim data to enhance trial integrity and credibility Clinical Trials, April 1, 2008; 5(2): 157 - 167. [Abstract] [PDF]

				C. C. Jaffe Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design Oncologist, April 1, 2008; 13(suppl_2): 14 - 18. [Abstract] [Full Text] [PDF]

				R. Pazdur Endpoints for Assessing Drug Activity in Clinical Trials Oncologist, April 1, 2008; 13(suppl_2): 19 - 21. [Abstract] [Full Text] [PDF]

				W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422. [Abstract] [Full Text] [PDF]

				E. P. Rock, J. A. Scott, D. L. Kennedy, R. Sridhara, R. Pazdur, and L. B. Burke Challenges to Use of Health-Related Quality of Life for Food and Drug Administration Approval of Anticancer Products J Natl Cancer Inst Monographs, October 1, 2007; 2007(37): 27 - 30. [Abstract] [Full Text] [PDF]

				N. Mayer-Hamblett, B. W. Ramsey, and R. A. Kronmal Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis Proceedings of the ATS, August 1, 2007; 4(4): 370 - 377. [Abstract] [Full Text] [PDF]

				D. P. Schuster The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 224 - 230. [Abstract] [Full Text] [PDF]

				A. G. Sorensen Magnetic Resonance As a Cancer Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3274 - 3281. [Abstract] [Full Text] [PDF]

				P. J. Neumann Emerging Lessons From The Drug Effectiveness Review Project Health Aff., July 1, 2006; 25(4): W262 - W271. [Abstract] [Full Text] [PDF]

				B. Starfield Threads and Yarns: Weaving the Tapestry of Comorbidity Ann. Fam. Med, March 1, 2006; 4(2): 101 - 103. [Full Text] [PDF]

				W. C. Johnson and G. Raghu Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Eur. Respir. J., November 1, 2005; 26(5): 755 - 758. [Full Text] [PDF]

				T. R. Fleming Objective Response Rate As a Surrogate End Point: A Commentary J. Clin. Oncol., August 1, 2005; 23(22): 4845 - 4846. [Full Text] [PDF]